Agonist vs Antagonist: How Peptides Act at Receptors

Understanding agonist vs antagonist behavior is one of the most useful pieces of pharmacology literacy for anyone reading the research peptide literature. Both terms describe how a molecule interacts with a receptor, yet they point to opposite functional outcomes: one switches a receptor on, the other prevents it from being switched on. This article explains what these terms mean at the receptor level, introduces the intermediate categories that sit between them, and illustrates each with peptides that have been studied in laboratory and preclinical settings.

Receptors as molecular switches

A receptor is a protein, often embedded in a cell membrane, that changes its shape or activity when a specific molecule binds to it. Many peptides studied in research act at G protein-coupled receptors (GPCRs), a large family that translates an outside signal into an inside-the-cell response. The molecule that binds is called a ligand. Two properties determine what a ligand does once it docks: affinity, how tightly it binds, and efficacy, how much it changes the receptor’s activity once bound. Affinity governs whether a molecule occupies the receptor at all; efficacy governs what happens next. This distinction is the foundation for telling an agonist from an antagonist.

Agonist vs antagonist: the core distinction

An agonist is a ligand that binds a receptor and activates it, producing a downstream cellular response that mimics the body’s own signaling molecule. A full agonist generates the maximal response the receptor is capable of. Glucagon-like peptide-1 (GLP-1) is a well-characterized peptide agonist: research has described how GLP-1 and engineered analogs bind the GLP-1 receptor and trigger G protein signaling that has been examined in the context of glucose regulation and appetite pathways in animal and cell models (Drucker, 2018). Newer investigational molecules act as agonists at more than one receptor simultaneously, and reviews have summarized how dual GIP/GLP-1 receptor agonists activate two distinct incretin receptors (Liu, 2024).

An antagonist, by contrast, binds the receptor but produces little or no activation on its own. Its function is to occupy the binding site and thereby block an agonist from acting. Antagonists have affinity but essentially zero efficacy. A classic peptide example is the GnRH (gonadotropin-releasing hormone) antagonist class, which reviews describe as producing a direct, rapid block of the GnRH receptor, preventing the hormonal cascade the natural agonist would otherwise drive (Coccia et al., 2004). In experimental pharmacology, antagonists are indispensable tools: they are used to confirm that an observed effect actually runs through a specific receptor.

Between the extremes: partial agonists, inverse agonists, and constitutive activity

The agonist/antagonist split is a useful starting point, but receptor behavior is a spectrum rather than a binary. A partial agonist binds and activates a receptor, but even at full occupancy it produces a submaximal response. This intermediate efficacy is of interest to researchers because a partial agonist can behave like a mild activator when a receptor is quiet and like a competitive brake when a full agonist is present. Studies using fixed-proportion agonist/antagonist mixtures have shown, at opioid and cannabinoid receptors, that net receptor activation can be tuned to any point between full activation and full blockade, providing a quantitative framework for thinking about intermediate efficacy (Selley et al., 2020).

Some receptors are not silent when empty. They show constitutive activity, signaling at a baseline level with no ligand bound. This opens the door to an inverse agonist, a ligand that binds and pushes activity below that baseline, the opposite direction from an agonist. The growth hormone secretagogue receptor (GHSR), the target of ghrelin, is a documented example: research in a rodent feeding model reported that GHSR carries high constitutive activity and that blockers of that baseline activity reduced binge-like intake, whereas blockers of ligand-evoked activity did not (Cornejo et al., 2019). This illustrates why “does it activate or block?” is sometimes too simple a question.

Why peptides make instructive examples

Peptides are attractive for studying receptor pharmacology because their sequences can be modified residue by residue, and small changes often shift a molecule along the agonist-to-antagonist spectrum. The synthetic ghrelin receptor agonist GHRP-2, for instance, has been examined in mouse models where its effects were reversed by a receptor-selective blocker, an experimental design that pins the observed activity to GHSR activation and demonstrates the agonist/antagonist logic in practice (Zeng et al., 2014). Reading peptide literature with the agonist vs antagonist framework in mind, and watching for the words partial and inverse, makes it far easier to interpret what a given study actually investigated.

References

• Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018. doi:10.1016/j.cmet.2018.03.001
• Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology. 2024. doi:10.3389/fendo.2024.1431292
• Selley DE, et al. Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures. J Pharmacol Exp Ther. 2020. doi:10.1124/jpet.120.000349
• Coccia ME, et al. GnRH antagonists. Eur J Obstet Gynecol Reprod Biol. 2004. doi:10.1016/j.ejogrb.2004.01.033
• Cornejo MP, et al. Growth hormone secretagogue receptor signalling and constitutive activity in a binge eating model. J Neuroendocrinol. 2019. doi:10.1111/jne.12785
• Zeng P, et al. Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects via the opioid receptor in mice. Peptides. 2014. doi:10.1016/j.peptides.2014.02.013

Citations retrieved from PubMed. Research Use Only. The compounds and peptides referenced here are discussed strictly for scientific and educational purposes. They are laboratory research materials and are not drugs, supplements, or products intended for human or animal consumption, diagnosis, treatment, or the prevention of any disease. Nothing above constitutes medical advice or a health claim; descriptions reflect only what published laboratory and preclinical research has investigated.